Members

  First name: Baptiste
  Last name: Gaborieau
  Function: PhD student
  Position: Medical Doctor / PhD student
  Email: baptiste.gaborieau
._
_.
inserm.fr

Research interest


My goal is to develop translational research, combining basic research with clinical research, and contributing to medical progress in the fight against infectious diseases through the use of bacteriophages. Most of my work is based on models prevention and treatment of bacterial pneumonia due to Escherichia coli by phages. I develop in collaboration with other French laboratories:
  • an evolutionary approach to better understand the host spectrum of phages.
  • pre-clinical approaches relating to the key elements for the effectiveness of the phage-therapy of the tripartite interaction between bacteria, bacteriophage and host (resistance, pharmacometry, immunity).

Education

Degree

2021 : M.D. Paris Descartes Medical School, Université de Paris Cité, France
2022 : PhD in Microbiology, Université de Paris Cité, France

Academic positions

2013-2019 : Resident, Paris Descartes Medical School, Université de Paris Cité, Assistance Publique-Hôpitaux de Paris, France

Research training (post doctoral)

2019-present : PhD student
* IAME U1137, Université de Paris Cité-INSERM, Paris France
* Bacteria, Bacteriophage, Host, Institut Pasteur, Paris, France

2017-2018 : Matser 2 Student, IAME U1137, Université de Paris Cité-INSERM, France

Exhaustive list of publications

2022


Delattre R, Seurat J, Haddad F, Nguyen TT, Gaborieau B, Kane R, Dufour N, Ricard JD, Guedj J, Debarbieux L
Combination of in vivo phage therapy data with in silico model highlights key parameters for pneumonia treatment efficacy.
Cell Reports 2022, 39, 110825.

Gaborieau B, Debarbieux L
The role of the animal host in the management of bacteriophage resistance during phage therapy.
Current Opinion in Virology 2022, 58, 101290.

Ferran AA, Lacroix MZ, Gourbeyre O, Huesca A, Gaborieau B, Debarbieux L, Bousquet-Mélou A
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Microbiology Spectrum 2022, 10, e0287422.

2020


Le Breton C, Besset S, Freita-Ramos S, Amouretti M, Billiet PA, Dao M, Dumont LM, Federici L, Gaborieau B, Longrois D, Postel-Vinay P, Vuillard C, Zucman N, Lebreton G, Combes A, Dreyfuss D, Ricard JD, Roux D
Extracorporeal membrane oxygenation for refractory COVID-19 acute respiratory distress syndrome.
Journal of Critical Care 2020, 60, 10-12.